SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Diane B. Miller, James P. O’Callaghan, Biomarkers of Parkinson’s disease: Present and future, Metabolism, 2015, 64, 3, S40

    CrossRef

  2. 2
    Fabrizio Stocchi, Neuroprotection in Parkinson's disease: a difficult challenge, The Lancet Neurology, 2015, 14, 8, 780

    CrossRef

  3. 3
    Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial, The Lancet Neurology, 2015, 14, 8, 795

    CrossRef

  4. 4
    Anette Schrag, Laura Horsfall, Kate Walters, Alastair Noyce, Irene Petersen, Prediagnostic presentations of Parkinson's disease in primary care: a case-control study, The Lancet Neurology, 2015, 14, 1, 57

    CrossRef

  5. 5
    J.A. Divisón Garrote, C. Escobar Cervantes, M. Seguí Díaz, Prediagnóstico de las presentaciones de la enfermedad de Parkinson en la atención primaria: un estudio de control de caso, SEMERGEN - Medicina de Familia, 2015, 41, 5, 284

    CrossRef

  6. 6
    Lucas Nürnberger, Christine Klein, Simon Baudrexel, Julia Roggendorf, Marcel Hildner, Shu Chen, Jun-Suk Kang, Rüdiger Hilker, Johann Hagenah, Ultrasound-based motion analysis demonstrates bilateral arm hypokinesia during gait in heterozygous PINK1 mutation carriers, Movement Disorders, 2015, 30, 3
  7. 7
    Naomi P. Visanji, Connie Marras, Lili-Naz Hazrati, Louis W. C. Liu, Anthony E. Lang, Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker, Movement Disorders, 2014, 29, 4
  8. 8
    Florian Krismer, Kurt A. Jellinger, Sonja W. Scholz, Klaus Seppi, Nadia Stefanova, Angelo Antonini, Werner Poewe, Gregor K. Wenning, Multiple system atrophy as emerging template for accelerated drug discovery in α-synucleinopathies, Parkinsonism & Related Disorders, 2014, 20, 8, 793

    CrossRef

  9. 9
    Daren Hanumunthadu, Mohammad H Dehabadi, Maria Francesca Cordeiro, Neuroprotection in glaucoma: current and emerging approaches, Expert Review of Ophthalmology, 2014, 9, 2, 109

    CrossRef

  10. 10
    Amaal AlDakheel, Lorraine V. Kalia, Anthony E. Lang, Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease, Neurotherapeutics, 2014, 11, 1, 6

    CrossRef

  11. 11
    Dilan Athauda, Thomas Foltynie, The ongoing pursuit of neuroprotective therapies in Parkinson disease, Nature Reviews Neurology, 2014, 11, 1, 25

    CrossRef

  12. 12
    Alex Iranzo, Eduard Tolosa, Ellen Gelpi, José Luis Molinuevo, Francesc Valldeoriola, Mónica Serradell, Raquel Sanchez-Valle, Isabel Vilaseca, Francisco Lomeña, Dolores Vilas, Albert LLadó, Carles Gaig, Joan Santamaria, Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study, The Lancet Neurology, 2013, 12, 5, 443

    CrossRef

  13. 13
    C. Warren Olanow, Jose A. Obeso, Fabrizio Stocchi, The Vatican Meeting on Neuroprotection for Parkinson's Disease, Movement Disorders, 2013, 28, 1
  14. 14
    Lawrence W Elmer, Robert A Hauser, Parkinson’s Disease: Medical and Surgical Treatment, 2013,

    CrossRef